Oxford Science reports 0% Barinthus ADS stake

Oxford Science Enterprises plc has updated its Schedule 13G to report zero beneficial ownership and 0.0% of Barinthus Biotherapeutics plc’s ADSs.

Rhea-AI Filing Summary

Barinthus Biotherapeutics plc (BRNS) reports that Oxford Science Enterprises plc has amended its Schedule 13G to show it no longer beneficially owns any American Depositary Shares of Barinthus. Oxford Science Enterprises reports 0 shares beneficially owned, representing 0.0% of the class, with no voting or dispositive power over any shares.

Key Figures

Beneficially owned shares: 0 shares Percent of class owned: 0.0% Sole voting power: 0 shares +3 more

6 metrics

Beneficially owned shares 0 shares Oxford Science Enterprises plc beneficial ownership of Barinthus ADSs

Percent of class owned 0.0% Oxford Science Enterprises plc percent of Barinthus ADS class

Sole voting power 0 shares Shares over which Oxford Science Enterprises plc has sole voting power

Shared voting power 0 shares Shares over which Oxford Science Enterprises plc has shared voting power

Sole dispositive power 0 shares Shares over which Oxford Science Enterprises plc has sole dispositive power

Shared dispositive power 0 shares Shares over which Oxford Science Enterprises plc has shared dispositive power

Key Terms

American Depositary Shares, beneficially owned, Sole Voting Power, Shared Dispositive Power, +1 more

5 terms

American Depositary Shares financial

"Title of class of securities: American Depositary Shares, each representing one Ordinary Share"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

beneficially owned financial

"Amount beneficially owned: 0"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power financial

"Sole Voting Power 0.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Shared Dispositive Power financial

"Shared Dispositive Power 0.00"

Percent of class financial

"Percent of class: 0.0 %"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does this Schedule 13G/A filing mean for Barinthus Biotherapeutics plc (BRNS)?

It shows that Oxford Science Enterprises plc now reports 0 shares beneficially owned and 0.0% of Barinthus Biotherapeutics plc’s American Depositary Shares, indicating it is no longer a beneficial owner of this class of securities.

How many BRNS American Depositary Shares does Oxford Science Enterprises plc now own?

Oxford Science Enterprises plc reports owning 0 American Depositary Shares of Barinthus Biotherapeutics plc, with no sole or shared power to vote or dispose of any shares.

What percentage of BRNS’s ADS class is held by Oxford Science Enterprises plc after this amendment?

After this amendment, Oxford Science Enterprises plc reports beneficial ownership of 0.0% of the class of Barinthus Biotherapeutics plc’s American Depositary Shares.

Does Oxford Science Enterprises plc have any voting power over BRNS shares?

No. Oxford Science Enterprises plc reports 0 shares with sole voting power and 0 shares with shared voting power, indicating no voting authority over Barinthus Biotherapeutics plc’s American Depositary Shares.

Does Oxford Science Enterprises plc have dispositive power over any BRNS securities?

No. The filing states Oxford Science Enterprises plc has 0 shares with sole dispositive power and 0 shares with shared dispositive power, reflecting no authority to dispose of Barinthus Biotherapeutics plc’s American Depositary Shares.

Who signed the Schedule 13G/A related to BRNS for Oxford Science Enterprises plc?

The Schedule 13G/A for Oxford Science Enterprises plc regarding Barinthus Biotherapeutics plc was signed by Antonia Jenkinson, identified as Chief Financial Officer, dated September 11, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 11:47 AM Accepted by SEC EDGAR 09/11/2026 - 11:47 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Barinthus Biotherapeutics plc.

(Name of Issuer)

American Depositary Shares, each representing one Ordinary Share

(Title of Class of Securities)

91864C107

(CUSIP Number)

09/09/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 91864C107

1

Names of Reporting Persons

Oxford Science Enterprises plc

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Barinthus Biotherapeutics plc.
(b)	Address of issuer's principal executive offices: 20400 CENTURY BLVD, SUITE 210, GERMANTOWN, MARYLAND, 20874
Item 2.
(a)	Name of person filing: Oxford Science Enterprises plc
(b)	Address or principal business office or, if none, residence: 46 Woodstock Road, Oxford OX2 6HT, United Kingdom
(c)	Citizenship: England, United Kingdom
(d)	Title of class of securities: American Depositary Shares, each representing one Ordinary Share
(e)	CUSIP No.: 91864C107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 0
(b)	Percent of class: 0.0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Oxford Science Enterprises plc

Signature:	/s/ Antonia Jenkinson
Name/Title:	Chief Financial Officer
Date:	09/11/2026